RSS Feed - Intellectual Property - Kaye Scholer LLP
Current Feed: http://www.kayescholer.com/practice/rss.xml?p=intellectual_property
Saul P. Morgenstern (10/22/14)
Saul Morgenstern, Co-Chair of the firm’s Antitrust practice, litigates complex disputes, class actions and multi-jurisdictional cases before US federal and state courts, international arbitral tribunals, the Federal Trade Commission and the US International Trade Commission, and represents clients in US Government, State and foreign investigations. He also advises companies with respect to the antitrust implications of mergers, acquisitions, joint ventures, trade association activities, distribution and pricing programs and other aspects of competitor and customer relations. Saul has represented clients across a broad spectrum of industries, including the chemical, computer hardware and software, energy, entertainment, insurance, financial, leisure, luxury consumer goods, pharmaceutical, publishing, real estate, telecommunications and toy industries.
Gerald Sobel (10/22/14)
Gerald Sobel is an experienced litigator whose practice is primarily in the areas of patent, antitrust and agreements. He is also active in mediation.
Vincent A. Sama (10/15/14)
Vincent Sama is Co-Chair of the Litigation Department, Chair of the Securities and Derivative Litigation Practice Group and a member of the firm's Executive Committee. He concentrates his practice in complex commercial litigation, securities and derivative litigation, internal and government investigations, international commercial disputes and arbitration.
Claudia R. Higgins (10/07/14)
Claudia Higgins joined Kaye Scholer following over two decades of distinguished service as an antitrust litigator with the Federal Trade Commission (FTC). An antitrust partner in the firm’s Complex Commercial Litigation department, Claudia represents Fortune 500 companies in significant antitrust matters, particularly high-profile mergers, acquisitions and joint ventures, as well as in private antitrust litigation and civil investigations by the FTC, the US Department of Justice (DOJ), and numerous international regulatory agencies. Her experience in antitrust matters spans a widely diverse set of industries, including consumer goods, defense and aerospace, natural resources, technology and health care.
Aaron Stiefel (09/30/14)
Aaron Stiefel, Co-Chair of the Intellectual Property Department, has represented leading research-based pharmaceutical and biotechnology companies, such as Pfizer Inc, and Novartis, in all aspects of complex patent litigations. His experience includes bringing and defending patent infringement actions concerning antibiotics, antihypertensives, antifungal medications, treatments for erectile dysfunction, the cloning of alpha-interferon, testing of blood for hepatitis C infection, monoclonal antibodies, contact lenses, surgical devices, methods for producing transgenic mice and data storage products. Aaron litigates against other research-based companies and has also litigated claims brought against generic drug manufacturers under the Hatch-Waxman Act. Aaron has counseled clients with respect to a host of patent law issues and has authored articles and lectured on patent law. Aaron has also represented pharmaceutical companies regarding false advertising and unfair competition claims. Aaron was recently recognized as an “IP Star” by Managing IP Handbook 2014, recommended by The Legal 500 United States 2013 and ranked in IAM Patent 1000 2014 for his work in patent litigation.
Soumitra (Sam) Deka (09/24/14)
Sam Deka focuses on patent litigation involving pharmaceutical, computer, and telecommunication technologies. He is a registered patent attorney licensed to practice before the U.S. Patent and Trademark Office. He also has substantial experience counseling clients about due diligence and merger and acquisition matters involving intellectual property.
Daniel P. DiNapoli (09/24/14)
Daniel DiNapoli concentrates his practice in patent, trade secret, and unfair competition litigation and counseling. His intellectual property practice includes litigation, arbitration, and advice regarding patents and trade secrets in biotechnology, pharmaceuticals, ANDA litigations, including ANDA litigation involving Pfizer’s blockbuster drugs Viagra® and Celebrex®, medical diagnostics, surgical devices, computers, computer software, and telecommunications. Dan was recently recognized as an “IP Star” by Managing IP Handbook 2014 and recommended by The Legal 500 United States 2013. He has also been named by Best Lawyers in America as Lawyer of the Year for 2012 in the New York City area in the field of biotechnology, by The American Lawyer Magazine as Litigator of the Month, by The American Lawyer Litigation Daily as Litigator of the Week, and by the 2011 Who’s Who Legal for life sciences in New York. He has been ranked in Best Lawyers in America in biotechnology law since 2008.